NeuroNOS announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead investigational therapy, BA-101, for the treatment of Glioblastoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air subsidiary granted orphan designation for malignant glioma treatment
- Beyond Air signs international LungFit PH distribution agreements
- Beyond Air’s Earnings Call Highlights Growth and Challenges
- Beyond Air: Strong Revenue Growth and Strategic Partnerships Drive Buy Rating
- Beyond Air price target lowered to $5 from $20 at Piper Sandler